Obrixtamig (BI 764532, OBT 620) is an CD3E/DLL3-targeting L-kappa-G1-h-CH2-CH3_L-lambda-G1-h-CH2-CH3 type human antibody. Obrixtamig is a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager. Obrixtamig can be used for research of DLL3-positive small cell lung cancer[1].
Molecular Weight:
(152.03 kDa)
Purity:
99.9
CAS Number:
[2851943-09-2]
Target:
CD3
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
